Mostrar el registro sencillo del ítem
dc.contributor.author
Pérez De Lis, Marta
dc.contributor.author
Retamozo, Maria Soledad
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Flores Chávez, Alejandra
dc.contributor.author
Kostov, Belchin
dc.contributor.author
Perez Alvarez, Roberto
dc.contributor.author
Brito Zerón, Pilar
dc.contributor.author
Ramos Casals, Manuel
dc.date.available
2018-11-07T18:07:57Z
dc.date.issued
2017-11
dc.identifier.citation
Pérez De Lis, Marta; Retamozo, Maria Soledad; Flores Chávez, Alejandra; Kostov, Belchin; Perez Alvarez, Roberto; et al.; Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry); Informa Healthcare; Expert Opinion On Drug Safety; 16; 11; 11-2017; 1255-1271
dc.identifier.issn
1474-0338
dc.identifier.uri
http://hdl.handle.net/11336/63904
dc.description.abstract
Introduction: Biological drugs are therapies designed to target a specific molecule of the immune system that have been linked with the development of autoimmune diseases. Areas covered: The BIOGEAS Registry currently collects information about nearly 13,000 reported cases of autoimmune diseases developed in patients exposed to biologics, including more than 50 different systemic and organ-specific autoimmune disorders, of which psoriasis (n=6375), inflammatory bowel disease (n=845), demyelinating CNS disease (n=803), interstitial lung disease (n=519) and lupus (n=369) were the most frequently reported. The main biologics involved were anti-TNF agents in 9133 cases (adalimumab in 4154, infliximab in 3078 and etanercept in 1681), immune checkpoint inhibitors in 913 (ipilimumab in 524 and nivolumab in 225), B-cell targeted therapies in 741 (rituximab in 678), and growth factor inhibitors in 549 cases (bevacizumab in 544). Even though targeting a particular immune molecule may be associated with an excellent clinical response in most patients, an unexpected autoimmune disease may arise in around 8 out of 10,000 exposed patients. Expert opinion: Following the increased use of biologics, the number and diversity of induced autoimmune diseases is increasing exponentially. Management of these disorders will be an increasing clinical challenge in the daily practice in the next years.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Informa Healthcare
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Anti-Tnf Agents
dc.subject
Autoimmune Disease
dc.subject
Big Data
dc.subject
Cancer
dc.subject
Drug-Induced Event
dc.subject
Growth Factor Inhibitors
dc.subject
Immune Checkpoint Inhibitors
dc.subject
Rituximab
dc.subject.classification
Medicina Critica y de Emergencia
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-10-22T18:37:18Z
dc.journal.volume
16
dc.journal.number
11
dc.journal.pagination
1255-1271
dc.journal.pais
Reino Unido
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
London
dc.description.fil
Fil: Pérez De Lis, Marta. Hospitalario Universitario de la Coruña; España
dc.description.fil
Fil: Retamozo, Maria Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina. Hospital Clínic; España. Hospital Privado Universitario de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
dc.description.fil
Fil: Flores Chávez, Alejandra. Hospital Clínic; España. Hospital de Especialidades; México. Universidad de Colima; México
dc.description.fil
Fil: Kostov, Belchin. Primary Care Research Group; España
dc.description.fil
Fil: Perez Alvarez, Roberto. Hospital Alvaro Cunqueiro; España
dc.description.fil
Fil: Brito Zerón, Pilar. Hospital Clínic; España. Hospital CIMA; España
dc.description.fil
Fil: Ramos Casals, Manuel. Hospital Clínic; España. Universidad de Barcelona; España
dc.journal.title
Expert Opinion On Drug Safety
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.1080/14740338.2017.1372421
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14740338.2017.1372421
Archivos asociados